Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

2.77
-0.0100-0.36%
Post-market: 2.69-0.0800-2.89%17:57 EST
Volume:1.09M
Turnover:3.05M
Market Cap:174.14M
PE:-1.88
High:3.04
Open:2.79
Low:2.60
Close:2.78
52wk High:4.22
52wk Low:0.6101
Shares:62.87M
Float Shares:2.50M
Volume Ratio:3.60
T/O Rate:43.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4708
EPS(LYR):-1.6776
ROE:-103.99%
ROA:-51.82%
PB:2.97
PE(LYR):-1.65

Loading ...

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

Prelude Therapeutics to Pause Development of Cancer Drug

Dow Jones
·
Nov 04, 2025

Prelude Therapeutics Inc. to report third quarter 2025 financial results

Reuters
·
Nov 04, 2025

Prelude Therapeutics Inc - Jane Huang Departs as President and Cmo of Prelude

THOMSON REUTERS
·
Nov 04, 2025

Prelude Therapeutics Announces Strategic Business Update

THOMSON REUTERS
·
Nov 04, 2025

Prelude Therapeutics Announces Exclusive Option Agreement With Incyte for JAK2V617F Inhibitor Program

Reuters
·
Nov 04, 2025

Prelude Therapeutics Announces Exclusive Option Agreement With Incyte to Advance Mutant Selective Jak2v617f Jh2 Inhibitors

THOMSON REUTERS
·
Nov 04, 2025

Prelude Therapeutics Inc - to Receive $35 Mln Upfront, $25 Mln Equity Investment

THOMSON REUTERS
·
Nov 04, 2025

Prelude Therapeutics: to GET $100 Mln IF Incyte Were to Exercise Option to Buy Program

THOMSON REUTERS
·
Nov 04, 2025

Press Release: Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Dow Jones
·
Nov 03, 2025

Prelude Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Prelude Therapeutics Files Initial Beneficial Ownership Statement for Director Katina Dorton

Reuters
·
Oct 21, 2025

Prelude Therapeutics Appoints Katina Dorton to Board of Directors, Succeeding Mardi Dier as Audit Committee Chair

Reuters
·
Oct 17, 2025

Prelude Therapeutics Announces Appointment of Katina Dorton, J.d., MBA to Its Board of Directors

THOMSON REUTERS
·
Oct 17, 2025

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 23, 2025

Prelude Therapeutics Regains Nasdaq Compliance

TIPRANKS
·
Sep 19, 2025